NextCure Competitors

Stocks . USA . 
Stock . NextCure
NXTC Stock  USD 13.37  0.22  1.62%   
NextCure competes with Q32 Bio, Plus Therapeutics, Boundless Bio, Verrica Pharmaceuticals, and AN2 Therapeutics; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing NextCure competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of NextCure to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out NextCure Correlation with its peers.
For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of NextCure competition on your existing holdings.
  
Build AI portfolio with NextCure Stock
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of NextCure's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
3.9613.7923.62
Details
Intrinsic
Valuation
LowRealHigh
5.0414.8724.70
Details
Naive
Forecast
LowNextHigh
5.9115.7525.58
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
10.0712.3514.63
Details

NextCure Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between NextCure and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of NextCure and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of NextCure does not affect the price movement of the other competitor.

High positive correlations

ITRM
+ 0.91
TAOX
JSPR
+ 0.8
BOLD
TAOX
+ 0.8
PLUR
ITRM
+ 0.78
JSPR
ITRM
+ 0.78
PLUR
ANTX
+ 0.7
BOLD
  

High negative correlations

TAOX
- 0.78
VRCA
ITRM
- 0.75
VRCA
PLUR
- 0.75
VRCA
VRCA
- 0.52
BOLD
JSPR
- 0.49
VRCA
ANTX
- 0.36
VRCA

Risk-Adjusted Indicators

There is a big difference between NextCure Stock performing well and NextCure Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze NextCure's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
QTTB  5.45  0.32  0.03 (0.65) 6.09 
(6.33)
 6.31 
(10.73)
 85.16 
PSTV  4.44 (0.41) 0.00 (0.08) 0.00 
 0.00 
 8.93 
(7.14)
 19.38 
BOLD  2.41  0.04 (0.01) 0.30  2.65 
(3.31)
 5.41 
(4.84)
 15.34 
VRCA  5.66  1.17  0.21  0.52  5.10 
(6.54)
 13.76 
(9.82)
 52.65 
ANTX  2.43  0.00  0.01  0.08  2.60 
(3.14)
 4.55 
(4.39)
 21.89 
JSPR  4.34 (0.72) 0.00 (0.39) 0.00 
 0.00 
 7.73 
(9.04)
 31.75 
INTS  14.58  4.80  0.39 (2,181) 9.08 
(25.90)
 12.20 
(14.04)
 433.59 
PLUR  3.48 (0.61) 0.00 (0.40) 0.00 
 0.00 
 9.24 
(6.23)
 31.25 
TAOX  6.39 (1.07) 0.00 (0.15) 0.00 
 0.00 
 14.89 
(11.10)
 44.55 
ITRM  4.45 (1.32) 0.00 (0.39) 0.00 
 0.00 
 9.38 
(8.82)
 35.34 
All Fundamental Data

NextCure Competitive Analysis

The better you understand NextCure competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, NextCure's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across NextCure's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
NXTC QTTB PSTV BOLD VRCA ANTX JSPR INTS PLUR TAOX
 1.62 
 13.37 
NextCure
 0.56 
 3.60 
Q32
 3.28 
 0.59 
Plus
 2.34 
 1.31 
Boundless
 1.23 
 8.02 
Verrica
 1.52 
 1.30 
AN2
 9.04 
 1.51 
Jasper
 2.33 
 0.42 
Intensity
 1.33 
 3.05 
Pluri
 5.24 
 5.06 
TAO
Market Volatility
(90 Days Market Risk)
Slightly risky
Dangerous
Dangerous
Very risky
Relatively risky
Dangerous
Risky
Out of control
Relatively risky
Very risky
Market Performance
(90 Days Performance)
Good
Weak
Weakest
Weak
Good
Weak
Weakest
Fair
Weakest
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
High
Risky
Risky
High
High
High
Low
Low
Risky
Risky
Current Valuation
(Equity Enterprise Value)
Under Valued
Over Valued
Under Valued
Under Valued
Under Valued
Over Valued
Under Valued
Under Valued
Under Valued
Fairly Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Hold
Strong Sell
Strong Sell
Strong Sell
Sell
Strong Sell
Current Ratio
33.87
N/A
2.81
12.8
1.25
28.17
9.56
N/A
8.46
N/A
Net Asset
80.86 M
92.33 M
6.63 M
206.41 M
54.13 M
92.09 M
79.9 M
4.78 M
38.68 M
17.73 M
Profit Margin
N/A
N/A
N/A
N/A
-0.84
N/A
N/A
N/A
N/A
N/A
EBITDA
(54.34 M)
(45.3 M)
(8.4 M)
(64.28 M)
(65.9 M)
3.23 M
(74.87 M)
(16.27 M)
(22.07 M)
(6.81 M)
Current Valuation
22.94 M
12.04 M
66.95 M
(39.16 M)
144.48 M
(25.75 M)
8.17 M
17.09 M
46.76 M
11.07 M
Price To Book
2.01
3.55
16.53
0.26
238.54
0.6
4.96
3.33
306.56
1.43
Operating Margin
N/A
N/A
-3.21
N/A
0.11
N/A
N/A
N/A
-16.64
-589.6
Retained Earnings
(380.14 M)
(234.81 M)
(493.48 M)
(201.47 M)
(307.03 M)
(205.78 M)
(240.87 M)
(66.78 M)
(443.06 M)
(47.17 M)
Current Asset
46.99 M
N/A
N/A
99.64 M
N/A
N/A
N/A
N/A
N/A
N/A
Beta
1.53
N/A
0.84
2.19
1.46
-0.031
3.07
4.21
0.57
2.04
Number Of Employees
43
26
21
64
71
22
27
5
127
4
Shares Outstanding
3.51 M
12.3 M
137.43 M
22.39 M
15.99 M
27.4 M
27.98 M
60.06 M
8.16 M
3.49 M
Cash Flow From Operations
(40.8 M)
(67.72 M)
(10.55 M)
(60.84 M)
(60.93 M)
(49.26 M)
(62.6 M)
(15.22 M)
(18.21 M)
(4.88 M)
Total Debt
5.95 M
18.9 M
3.37 M
47.63 M
45.94 M
10.24 M
1.81 M
138 K
34.05 M
10.96 M
Return On Equity
-1.17
-4.92
-5.22
-0.45
-15.47
-0.46
-1.91
-2.35
-10.22
-1.55
Return On Asset
-0.58
-0.33
-0.66
-0.25
-0.26
-0.28
-0.73
-1.02
-0.35
-0.18
Number Of Shares Shorted
26.71 K
428.9 K
7.07 M
71.22 K
380.56 K
41.35 K
3.46 M
2.95 M
9.1 K
227.24 K
Book Value Per Share
8.84
-1.5
0.038
4.92
-1.8
2.21
0.41
0.15
-0.87
6.89
Current Liabilities
5.53 M
N/A
N/A
104 K
N/A
N/A
N/A
N/A
N/A
N/A
Total Asset
80.86 M
92.33 M
6.63 M
206.41 M
54.13 M
92.09 M
79.9 M
4.78 M
38.68 M
17.73 M
Debt To Equity
0.01
N/A
0.53
0.078
2.69
N/A
0.068
N/A
0.89
N/A
Short Ratio
0.48
0.05
1.1
0.35
0.91
0.69
0.9
0.88
1.77
3.27
Target Price
17.67
15.0
7.16
3.0
16.5
1.0
12.33
2.92
12.0
N/A
Shares Owned By Institutions
32.8
64.32
3.8
57.5
20.06
39.35
73.79
7.01
17.17
1.7
Market Capitalization
47.64 M
44.05 M
80.41 M
28.65 M
128.24 M
36.17 M
57.37 M
26.07 M
34.09 M
33.48 M
Price To Earning
-25.44
N/A
N/A
-7.22
N/A
3.96
N/A
N/A
N/A
N/A
Price To Earnings To Growth
0.03
N/A
N/A
-1.09
0.03
N/A
N/A
N/A
N/A
N/A
Price To Sales
9.52
N/A
15.29
N/A
4.16
N/A
N/A
N/A
21.01
8449.42
Net Income
(55.65 M)
(47.73 M)
(12.98 M)
(65.36 M)
(76.58 M)
(51.32 M)
(71.27 M)
(16.27 M)
(23.25 M)
(12.77 M)
Earnings Per Share
-23.81
-3.4
-0.96
-2.66
-2.87
-1.13
-5.82
-0.55
-3.56
-21.31
Shares Owned By Insiders
20.16
6.45
1.54
11.39
51.84
25.38
1.04
8.77
36.36
1.66
Revenue
N/A
N/A
5.82 M
N/A
7.57 M
N/A
N/A
N/A
1.34 M
N/A
Working Capital
62.23 M
65.41 M
(10.29 M)
146.25 M
22.17 M
76.02 M
60.57 M
1.61 M
(10.23 M)
16.71 M
Cash And Equivalents
185.49 M
N/A
20.27 M
351.46 M
14.4 M
113.39 M
60.81 M
N/A
55.02 M
N/A
Cash Per Share
6.68
N/A
0.6
7.68
0.35
5.84
1.6
N/A
1.69
N/A
Gross Profit
(54.2 M)
(26.39 M)
(2.37 M)
N/A
20.66 M
N/A
N/A
N/A
654 K
3.96 K
Day Typical Price
13.42
3.6
0.59
1.3
8.08
1.31
1.57
0.43
3.03
5.17
Accumulation Distribution
3887.59
9775.94
0.0492
0.0451
0.0458
3098.54
344334.0
31665.45
63.98
10972.01
Market Facilitation Index
0.0
0.0
0.03
0.06
0.38
0.0
N/A
N/A
0.0
0.0
Daily Balance Of Power
(0.21)
0.08
(0.67)
0.5
(0.26)
(0.40)
(0.65)
(0.50)
0.8
(0.64)
Period Momentum Indicator
(0.22)
0.02
(0.02)
0.03
(0.10)
(0.02)
(0.15)
(0.01)
0.04
(0.28)
Rate Of Daily Change
0.98
1.01
0.97
1.02
0.99
0.98
0.91
0.98
1.01
0.95
Day Median Price
13.45
3.61
0.6
1.3
8.11
1.32
1.61
0.43
3.03
5.22
Price Action Indicator
(0.19)
0.005
(0.01)
0.025
(0.14)
(0.03)
(0.17)
(0.01)
0.045
(0.30)
Coefficient Of Variation
593.85
3667.24
(2,789)
5083.92
611.88
3212.41
(956.33)
1051.1
(1,056)
(1,250)
Mean Deviation
6.27
5.45
4.44
2.41
5.66
2.43
4.34
14.58
3.48
6.39
Jensen Alpha
1.54
0.3246
(0.41)
0.0391
1.17
(0)
(0.72)
4.8
(0.61)
(1.07)
Total Risk Alpha
0.5279
(0.95)
(0.80)
(0.32)
0.4221
(0.34)
(1.23)
(0.93)
(1.09)
(1.64)
Sortino Ratio
0.209
0.03
N/A
(0.01)
0.2122
0.0103
N/A
0.3864
N/A
N/A
Downside Variance
54.96
45.77
N/A
11.24
38.36
9.55
N/A
148.79
N/A
N/A
Standard Deviation
9.76
10.91
5.29
3.27
8.62
4.06
5.6
50.53
5.18
8.43
Kurtosis
4.66
35.61
(0.88)
1.5
5.02
11.36
1.12
57.24
3.82
0.9642
Potential Upside
15.65
6.31
8.93
5.41
13.76
4.55
7.73
12.2
9.24
14.89
Treynor Ratio
1.47
(0.65)
(0.08)
0.3014
0.5152
0.0834
(0.39)
(2,181)
(0.40)
(0.15)
Maximum Drawdown
60.54
85.16
19.38
15.34
52.65
21.89
31.75
433.59
31.25
44.55
Variance
95.31
118.97
27.94
10.69
74.28
16.45
31.32
2553.53
26.79
71.05
Market Risk Adjusted Performance
1.48
(0.64)
(0.07)
0.3114
0.5252
0.0934
(0.38)
(2,181)
(0.39)
(0.14)
Risk Adjusted Performance
0.1345
0.0296
(0.02)
0.0224
0.1307
0.0313
(0.07)
0.0806
(0.06)
(0.05)
Skewness
1.32
5.19
0.2252
0.6374
1.62
2.71
(0.63)
7.42
1.24
0.6409
Semi Deviation
6.4
6.09
N/A
2.65
5.1
2.6
N/A
9.08
N/A
N/A
Information Ratio
0.1587
0.0186
(0.05)
(0.01)
0.1525
0.0079
(0.12)
0.0933
(0.11)
(0.09)
Value At Risk
(8.76)
(10.73)
(7.14)
(4.84)
(9.82)
(4.39)
(9.04)
(14.04)
(6.23)
(11.10)
Expected Short fall
(7.41)
(6.33)
N/A
(3.31)
(6.54)
(3.14)
N/A
(25.90)
N/A
N/A
Downside Deviation
7.41
6.77
N/A
3.35
6.19
3.09
N/A
12.2
N/A
N/A
Semi Variance
40.97
37.14
N/A
7.03
26.01
6.77
N/A
82.53
N/A
N/A

NextCure Competition Performance Charts

Five steps to successful analysis of NextCure Competition

NextCure's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by NextCure in relation to its competition. NextCure's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of NextCure in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact NextCure's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to NextCure, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your NextCure position

In addition to having NextCure in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Money Funds Thematic Idea Now

Money Funds
Money Funds Theme
Funds or Etfs that invest most if their asset in companies from financial sector such as commercial banks, insurance companies, investment funds, and real estate. The Money Funds theme has 19 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Money Funds Theme or any other thematic opportunities.
View All  Next Launch
When determining whether NextCure offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NextCure's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nextcure Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nextcure Stock:
How To Invest In NextCure
Details
Is NextCure Stock a good investment?
Details
What is NextCure's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out NextCure Correlation with its peers.
For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NextCure. If investors know NextCure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NextCure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of NextCure is measured differently than its book value, which is the value of NextCure that is recorded on the company's balance sheet. Investors also form their own opinion of NextCure's value that differs from its market value or its book value, called intrinsic value, which is NextCure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NextCure's market value can be influenced by many factors that don't directly affect NextCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between NextCure's value and its price as these two are different measures arrived at by different means. Investors typically determine if NextCure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NextCure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY